The prediction of immune cell infiltration shows that the TME of high-risk patients may enrich more Tregs and CD8+cells, which have been proved to inhibit tumor immune response in previous studies, thus helping tumor cells escape immune monitoring (Shang, et al., 2015; Tanaka and Sakaguchi, 2017; Dai, et al., 2021; Gao, et al., 2022). The gene discussed is CD8A; the disease is neoplasm.